<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583063</url>
  </required_header>
  <id_info>
    <org_study_id>15328B</org_study_id>
    <nct_id>NCT00583063</nct_id>
  </id_info>
  <brief_title>Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers</brief_title>
  <official_title>A Pharmacokinetic Interaction Study of Rapamycin (Sirolimus) and SU11248 (Sunitinib) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interactions</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the combined drug regimen</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to drug regimen</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>25 mg daily (oral dosing)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>4 mg daily (oral dosing)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic or unresectable cancer for which standard treatments do not exist or are no&#xD;
             longer effective or cancers where evidence of efficacy of single agent sunitinib or&#xD;
             single agent mTOR inhibitor has been demonstrated&#xD;
&#xD;
          -  Measurable or non-measurable disease.&#xD;
&#xD;
          -  No prior treatments for 4 weeks before starting study&#xD;
&#xD;
          -  No ongoing toxicities from previous treatments&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Performance status 2 or better&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
               -  No transfusions of packed red blood cells within 1 week of starting treatment. A&#xD;
                  hemoglobin of 9.0 g/dL or greater is recommended. Patients should not be&#xD;
                  transfused for protocol participation.&#xD;
&#xD;
               -  Leukocytes greater than or equal to 3,000/μL&#xD;
&#xD;
               -  Absolute neutrophil count greater than or equal to 1,500/μL&#xD;
&#xD;
               -  Platelets greater than or equal to 100,000/μL&#xD;
&#xD;
               -  Total bilirubin less than or equal to 1.5 x ULN&#xD;
&#xD;
               -  AST and ALT less than or equal to 2.5x ULN (less than or equal to 5x ULN if liver&#xD;
                  function abnormalities are due to underlying disease)&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR&#xD;
&#xD;
               -  Creatinine clearance &gt; 60 mL/min/1.73 m2&#xD;
&#xD;
               -  PT or INR within normal institutional limits&#xD;
&#xD;
               -  Serum calcium within normal institutional limits&#xD;
&#xD;
          -  QTc &lt; 500 msec.&#xD;
&#xD;
          -  Patients with prior anthracycline exposure or that have received central thoracic&#xD;
             radiation must have NYHA class I cardiac function&#xD;
&#xD;
          -  Must agree to use adequate birth control&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatments within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of entering&#xD;
             the study or those who have not recovered from adverse events due prior treatments&#xD;
&#xD;
          -  Current treatment with other investigational agents.&#xD;
&#xD;
          -  Prior therapy with a VEGFR or mTOR inhibitor&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to rapamycin or sunitinib.&#xD;
&#xD;
          -  QTc prolongation (QTc interval equal to or greater than 500 msec) or other significant&#xD;
             ECG abnormalities&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Patients with any of the following conditions are excluded:&#xD;
&#xD;
               -  Serious or non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
                  abscess within 28 days of treatment.&#xD;
&#xD;
               -  Known active infection&#xD;
&#xD;
               -  Major surgery or radiation therapy within 4 weeks of starting the study&#xD;
                  treatment.&#xD;
&#xD;
               -  NCI CTCAE Version 3.0 grade 3 hemorrhage within 4 weeks of starting the study&#xD;
                  treatment.&#xD;
&#xD;
               -  History of CVA or transient ischemic attack within 12 months prior to study&#xD;
                  entry.&#xD;
&#xD;
               -  History of myocardial infarction, cardiac arrhythmia, stable/unstable angina,&#xD;
                  symptomatic congestive heart failure, or coronary/peripheral artery bypass graft&#xD;
                  or stenting within 12 months prior to study entry.&#xD;
&#xD;
               -  History of pulmonary embolism within the past 12 months.&#xD;
&#xD;
               -  Class III or IV heart failure as defined by the NYHA functional classification&#xD;
                  system&#xD;
&#xD;
               -  Ongoing cardiac dysrhythmias&#xD;
&#xD;
               -  Poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or&#xD;
                  diastolic blood pressure of 90 mmHg or higher)&#xD;
&#xD;
               -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained&#xD;
                  in the normal range with medication&#xD;
&#xD;
               -  History of interstitial lung disease&#xD;
&#xD;
          -  Patients with severe immunodeficient states (as judged by the treating physician)&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for interactions with the study drugs&#xD;
&#xD;
          -  Use of certain medications (as determined by the investigator)&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk or interfere with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

